Venn Life Sciences is confident on its outlook, saying the strong momentum in 2016 has continued into this year
Showing 25 of 1631
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year
OptiBiotix is seeking an AIM listing for its SkinBioTherapeutics subsidiary
Redx Pharma is confident on its 2017 outlook as it develops a pipeline of cancer treatments and restructures the business
A compensation payment of £4mln is now due from Sinclair on or before 30 April 2017, with a further £1mln due on or before 30 June 2018.
Sales of PeproStat can be as high as US$500mln believes Ergomed
The buyback offer would, if completed, be prior to the commencement of the separation and would be at a price of 21.5p per share
The transaction provides an opportunity to transform Circassia's product portfolio and commercial presence.
Shares in Hikma Pharmaceuticals have gained today after it reported a better-than-expected drop in full year profit
The company’s technology will be used to accelerate the “discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines”.
The broker Rodman looked at VolitionRx;s results and the potential ahead
The life sciences group said the accelerated book-build offering saw around 7.884 mln new shares placed at 52p each, a modest discount to last night’s closing share price
The group also said it “remains committed to ensure a secure financial position that can facilitate the commercialisation of the LIGHT system and crystallise the significant shareholder value associated with the provision of affordable proton therapy”
The City broker says OptiBiotix is “well-positioned” to be a leader in the growing microbiome space
The deal is with Sacco, one of Europe’s leading probiotic manufacturers and raw ingredients suppliers.
“Our clear preference is for specialty-focus and growth in the context of a strong-catalyst driven thematic or deep value,” Barclays said in a brief note to clients.
The studies were performed at Queen's Medical Centre and Institut Pasteur
The company’s AP101 has been developed to treat Epidermolysis Bullosa (EB), which leaves suffers with exceptionally fragile skin.
Ipsos predicts peak OTC or without prescription annual sales for MED2002 in excess of US$650mln
The latest version of the company’s blood gases monitor only launched in December, but initial reaction from customers has been “very encouraging”
The group, which floated in London last October, reported an increase in revenue to $1.7bn in the year ended 31 December 2016, from $1.6bn a year earlier
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
Sphere’s Proxima 4 blood gases monitors launched in December and first sales have already been achieved, while more than 20 other hospitals have shown an interest
The world-renowned university has snapped up 50,000 shares in the drug discoverer
The initial agreement is for funding of up to £26mln, although, subject to certain conditions, that figure could double